Kamada Licenses Alvotech Biosimilars In Israel
First Launch, Teriparatide, Is Slated For 2022
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
You may also be interested in...
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.
Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.